Search Results - "Blauvelt, A"

Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data by Deodhar, A, Mease, P J, McInnes, I B, Baraliakos, X, Reich, K, Blauvelt, A, Leonardi, C, Porter, B, Das Gupta, A, Widmer, A, Pricop, L, Fox, T

“…Secukinumab, a fully human immunoglobulin G1-kappa monoclonal antibody that directly inhibits interleukin (IL)-17A, has been shown to have robust efficacy in…”
Get full text

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2) by Wollenberg, A., Blauvelt, A., Guttman‐Yassky, E., Worm, M., Lynde, C., Lacour, J.‐P., Spelman, L., Katoh, N., Saeki, H., Poulin, Y., Lesiak, A., Kircik, L., Cho, S.H., Herranz, P., Cork, M.J., Peris, K., Steffensen, L.A., Bang, B., Kuznetsova, A., Jensen, T.N., Østerdal, M.L., Simpson, E.L.

“…Summary Background Tralokinumab, a fully human monoclonal antibody, specifically neutralizes interleukin‐13, a key cytokine driving peripheral inflammation in…”
Get full text

Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical trial by Warren, R.B., Blauvelt, A., Poulin, Y., Beeck, S., Kelly, M., Wu, T., Geng, Z., Paul, C.

“…Summary Background Patients with plaque psoriasis treated with biologic therapies need more efficacious, safe and convenient treatments to improve quality of…”
Get full text

Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE) by Blauvelt, A., Prinz, J.C., Gottlieb, A.B., Kingo, K., Sofen, H., Ruer-Mulard, M., Singh, V., Pathan, R., Papavassilis, C., Cooper, S.

“…Summary Background Secukinumab, a fully human anti‐interleukin‐17A monoclonal antibody, demonstrated efficacy and safety in moderate‐to‐severe plaque psoriasis…”
Get full text

Laboratory safety of dupilumab in moderate‐to‐severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS) by Wollenberg, A., Beck, L.A., Blauvelt, A., Simpson, E.L., Chen, Z., Chen, Q., Shumel, B., Khokhar, F.A., Hultsch, T., Rizova, E., Rossi, A.B., Graham, N.M.H., Pirozzi, G., Lu, Y., Ardeleanu, M.

“…Summary Background Dupilumab [a monoclonal antibody blocking the shared receptor subunit for interleukin (IL)‐4 and IL‐13] is approved for patients aged ≥ 12…”
Get full text

Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double‐blinded, controlled studies (UNCOVER‐1, UNCOVER‐2, UNCOVER‐3) by Papp, K.A., Leonardi, C.L., Blauvelt, A., Reich, K., Korman, N.J., Ohtsuki, M., Paul, C., Ball, S., Cameron, G.S., Erickson, J., Zhang, L., Mallbris, L., Griffiths, C.E.M.

“…Summary Background Ixekizumab, a high‐affinity monoclonal antibody that selectively targets interleukin (IL)‐17A, is approved for the treatment of…”
Get full text

A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis by Papp, K.A., Reich, K., Paul, C., Blauvelt, A., Baran, W., Bolduc, C., Toth, D., Langley, R.G., Cather, J., Gottlieb, A.B., Thaçi, D., Krueger, J.G., Russell, C.B., Milmont, C.E., Li, J., Klekotka, P.A., Kricorian, G., Nirula, A.

“…Summary Background The interleukin‐17 cytokine family plays a central role in psoriasis pathogenesis. Objectives To evaluate the efficacy and safety of…”
Get full text

Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks by Reich, K., Warren, R.B., Iversen, L., Puig, L., Pau‐Charles, I., Igarashi, A., Ohtsuki, M., Falqués, M., Harmut, M., Rozzo, S., Lebwohl, M.G., Cantrell, W., Blauvelt, A., Thaçi, D.

“…Summary Background Tildrakizumab is a specific anti‐interleukin‐23p19 monoclonal antibody approved for the treatment of plaque psoriasis. Objectives To…”
Get full text

Conjunctivitis in dupilumab clinical trials by Akinlade, B., Guttman‐Yassky, E., Bruin‐Weller, M., Simpson, E.L., Blauvelt, A., Cork, M.J., Prens, E., Asbell, P., Akpek, E., Corren, J., Bachert, C., Hirano, I., Weyne, J., Korotzer, A., Chen, Z., Hultsch, T., Zhu, X., Davis, J.D., Mannent, L., Hamilton, J.D., Teper, A., Staudinger, H., Rizova, E., Pirozzi, G., Graham, N.M.H., Shumel, B., Ardeleanu, M., Wollenberg, A.

“…Summary Background Dupilumab blocks the shared receptor component for interleukin (IL)‐4 and IL‐13. It is approved in the U.S.A. for patients aged ≥ 12 years…”
Get full text

Response to critical appraisal of LIBERTY AD CHRONOS by Blauvelt, A., Shumel, B.

“…Linked Article: Thomson et al. Br J Dermatol 2018; 178:897–902…”
Get full text

Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis by Gordon, K.B., Lebwohl, M., Papp, K.A., Bachelez, H., Wu, J.J., Langley, R.G., Blauvelt, A., Kaplan, B., Shah, M., Zhao, Y., Sinvhal, R., Reich, K.

“…Summary Background Risankizumab has demonstrated efficacy and safety in patients with moderate‐to‐severe plaque psoriasis in randomized clinical trials…”
Get full text

Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches by Blauvelt, A., Lacour, J.‐P., Fowler, J.F., Weinberg, J.M., Gospodinov, D., Schuck, E., Jauch‐Lembach, J., Balfour, A., Leonardi, C.L.

“…Summary Background Adalimumab is used to treat several inflammatory diseases, including plaque psoriasis. GP2017 is a proposed adalimumab biosimilar…”
Get full text

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial by Blauvelt, A., Leonardi, C., Elewski, B., Crowley, J.J., Guenther, L.C., Gooderham, M., Langley, R.G., Vender, R., Pinter, A., Griffiths, C.E.M., Tada, Y., Elmaraghy, H., Lima, R.G., Gallo, G., Renda, L., Burge, R., Park, S.Y., Zhu, B., Papp, K.

“…Summary Background Significantly more patients with moderate‐to‐severe plaque psoriasis treated with the interleukin (IL)‐17A inhibitor ixekizumab vs. the…”
Get full text

Efficacy and safety of continuous every‐2‐week dosing of ixekizumab over 52 weeks in patients with moderate‐to‐severe plaque psoriasis in a randomized phase III trial (IXORA‐P) by Langley, R.G., Papp, K., Gooderham, M., Zhang, L., Mallinckrodt, C., Agada, N., Blauvelt, A., Foley, P., Polzer, P.

“…Summary Background Ixekizumab is an interleukin‐17A antagonist approved for treatment of moderate‐to‐severe plaque psoriasis with a recommended 160‐mg starting…”
Get full text

Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate‐to‐severe psoriasis: a pooled analysis of two randomized controlled trials by Blauvelt, A., Sofen, H., Papp, K., Gooderham, M., Tyring, S., Zhao, Y., Lowry, S., Mendelsohn, A., Parno, J., Reich, K.

“…Background Two randomized controlled trials (reSURFACE 1 and 2) have demonstrated the effectiveness of tildrakizumab, a high‐affinity, humanized, IgG1κ,…”
Get full text

Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: analysis of two randomized controlled trials by Hsu, S., Green, L.J., Lebwohl, M.G., Wu, J.J., Blauvelt, A., Jacobson, A.A.

“…Summary Background Obesity is associated with psoriasis and negatively affects response to therapy. Objectives To evaluate the efficacy and safety of…”
Get full text

Decreased quality of life in people with psoriasis and psoriatic arthritis vs. people with psoriasis alone: data from a national US survey by Gondo, G.C., Merola, J.F., Bell, S.J., Blauvelt, A.

Get full text

Efficacy of guselkumab in subpopulations of patients with moderate‐to‐severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies by Gordon, K.B., Blauvelt, A., Foley, P., Song, M., Wasfi, Y., Randazzo, B., Shen, Y.K., You, Y., Griffiths, C.E.M.

“…Summary Background Significant advances have been made in the treatment of moderate‐to‐severe plaque psoriasis with biological therapies; however, these agents…”
Get full text

Safety of tildrakizumab for moderate‐to‐severe plaque psoriasis: pooled analysis of three randomized controlled trials by Blauvelt, A., Reich, K., Papp, K.A., Kimball, A.B., Gooderham, M., Tyring, S.K., Sinclair, R., Thaçi, D., Li, Q., Cichanowitz, N., Green, S., La Rosa, C.

“…Summary Background Short‐term interleukin‐23p19 inhibition by tildrakizumab improves plaque psoriasis and appears to be well tolerated. Objectives Safety and…”
Get full text

Super‐response to guselkumab treatment in patients with moderate‐to‐severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance by Reich, K., Gordon, K.B., Strober, B., Langley, R.G., Miller, M., Yang, Y.‐W., Shen, Y.‐K., You, Y., Zhu, Y., Foley, P., Blauvelt, A.

“…Background Psoriasis is a chronic immune‐mediated inflammatory skin disease that often leads to a diminished quality of life. Goals of treating patients with…”
Get full text